GABBRIELLE KNABE: Open Payments
NPI 1891233896 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$364 in 20 payments from 8 companies in 2025. Trend: 2023 $258 · 2024 $187 · 2025 $364
Food & beverage: $364
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 6 | $107 |
| ABBVIE INC. | 4 | $86 |
| Dexcom, Inc. | 3 | $54 |
| Novo Nordisk Inc | 3 | $45 |
| Astellas Pharma US Inc | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Exact Sciences Corporation | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
Products named: FREESTYLE LIBRE 3, Dexcom G6 Transmitter, VRAYLAR, Ozempic, Veozah, PROCLAIM, MAVYRET, CAPLYTA.
Industry payments across AZ — which companies pay providers there.
